Literature DB >> 31260641

Immunotherapy for Urothelial Cancer: Where Are the Randomized Trials?

Francisco E Vera-Badillo1, Ian F Tannock2, Christopher M Booth1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31260641     DOI： 10.1200/JCO.18.02257

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  4 in total

Review 1.  Advances in Transversal Topics Applicable to the Care of Bladder Cancer Patients in the Real-World Setting.

Authors:  Marga Garrido Siles; Antonio López-Beltran; Paula Pelechano; Ana María García Vicente; Regina Gironés Sarrió; Eva González-Haba Peña; Alfredo Rodríguez Antolín; Almudena Zapatero; José Ángel Arranz; Miguel Ángel Climent
Journal:  Cancers (Basel)       Date:  2022-08-17       Impact factor: 6.575

Review 2.  Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments.

Authors:  Dario Trapani; Kiu Tay-Teo; Megan E Tesch; Felipe Roitberg; Manju Sengar; Sara C Altuna; Michael J Hassett; Armando A Genazzani; Aaron S Kesselheim; Giuseppe Curigliano
Journal:  Curr Oncol       Date:  2022-08-16       Impact factor: 3.109

Review 3.  Current Perspectives on Immunotherapy in the Peri-Operative Setting of Muscle-Infiltrating Bladder Cancer.

Authors:  Paolo Andrea Zucali; Nadia Cordua; Federica D'Antonio; Federica Borea; Matteo Perrino; Fabio De Vincenzo; Armando Santoro
Journal:  Front Oncol       Date:  2020-10-21       Impact factor: 6.244

4.  Combined radiotherapy and immunotherapy in urothelial bladder cancer: harnessing the full potential of the anti-tumor immune response.

Authors:  Mame Daro-Faye; Wassim Kassouf; Luis Souhami; Gautier Marcq; Fabio Cury; Tamim Niazi; Paul Sargos
Journal:  World J Urol       Date:  2020-09-11       Impact factor: 4.226
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.